Black Mountain Gold USA Corp. Receives Assay Results from Channel Sampling on Its Mohave Gold Project

Black Mountain
Cannot view this image? Visit: https://i2.wp.com/orders.newsfilecorp.com/files/4674/86606_e2b85facc4a78b3a_001.jpg?w=570&ssl=1

Black Mountain Gold USA Corp. (TSXV: BMG) (“BMG” or the “Company”) is pleased to announce it has received encouraging assay results from its recent mechanical rock chip-channel sampling program at its Mohave Gold Project in Mohave County, Arizona. Channel sampling was completed at several gold prospects in the northern half of the Project and confirmed the widespread nature of gold mineralization outlined in the M3 Metals sampling program in 2020 (see M3 Metals press release dated May 5, 2020) returning values up to 53.80 g/t Au and 94.2 g/t Ag over 2.8m. read more

Gran Colombia Announces Multiple High-Grade Drill Results From the 2021 In-Mine and Brownfield Drilling Campaigns at Its Segovia Operations; Success Continues at the Brownfield Vera Project Including 31.78 g/t Au and 8,150.0 g/t Ag Over 0.30 Meters

T.GCM, Gran Colombia, gold, Colombia

Gran Colombia Gold Corp. (TSX: GCM, OTCQX: TPRFF) (“Gran Colombia” or the “Company”) announced today multiple high-grade intercepts from the latest 62 diamond drill holes, totaling 13,056 meters, from the 2021 in-mine and near-mine drilling programs and a further 11 diamond drill holes, totaling 3,190 meters, from the 2021 brownfield drilling programs at its Segovia Operations. The Company also announced the assay results from four additional kick-off diamond drill holes (2,319 meters) from the ongoing directional drilling program at the El Silencio Deep Zone. read more

Lexaria Provides Progress Report on Six R&D Programs

-All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine -These studies are part of Lexaria’s 2021 applied R&D program intended to enable opportunities for strategic partnerships
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development (R&D) program. Other studies actively underway and planned will be reported on separately. read more